[Central dopaminergic receptors (Part II): pathophysiological and therapeutic considerations].
The five subtypes of dopaminergic receptors exhibit different transduction, cerebral localization, regulation, pharmacological, and physiological roles, explaining their multiple pathophysiological implications in different neuropsychiatric conditions which result, at least in part from anomalous dopaminergic neurotransmission: Parkinson's disease, schizophrenia, addiction, migraine, mode disorders, Gilles de la Tourette disease, hyperactivity syndrome with attention deficit. The wide range of pharmacological implications explains the diversity of the therapeutic approaches perspectives for development of new drugs for these neuropsychiatric conditions.
Bordet
R
R
EA1046, Laboratoire de Pharmacologie, Faculté de Médecine, Université de Lille 2, Lille.
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002490:Central Nervous System / Q000378:metabolism* / Q000503:physiopathology; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000378:metabolism* / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000503:physiopathology / Q000534:rehabilitation; D005879:Tourette Syndrome / Q000188:drug therapy
D015259:Dopamine Agents; D011954:Receptors, Dopamine